首頁 › 肺癌 › 緬因 › South Portland
South Portland, ME 的 肺癌 臨床試驗
6 項針對 肺癌 的研究正在 South Portland（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
- MaineHealth Urology - South Portland, South Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
招募中3 期
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
招募中3 期
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
其他城市的 肺癌 試驗
- Houston, TX78 項研究
- Boston, MA62 項研究
- New York City, NY60 項研究
- Los Angeles, CA45 項研究
- Arlington, VA41 項研究
- Washington, DC41 項研究
- Chicago, IL41 項研究
- Nashville, TN40 項研究
- Baltimore, MD40 項研究
- St. Louis, MO39 項研究
- Columbus, OH37 項研究
- Philadelphia, PA36 項研究
South Portland 的其他研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。